ITRM ITERUM THERAPEUTICS PLC Investments/Divestments 8-K Filing 2023 - Clinical Trial Enrollment Completion Iterum Therapeutics plc announced the completion of patient enrollment in its clinical trial comparing oral sulopenem to oral Augmentin for the treatment of urinary tract infections. They expect to report topline data in Q1 2024 and resubmit their New Drug Application in Q2 2024.Get access to all SEC 8-K filings of the ITERUM THERAPEUTICS PLC